Thesis (doctoral)--Lund University, 1994. / Added t.p. with thesis statement inserted.

Thesis (doctoral)--Lund University, 1994. / Added t.p. with thesis statement inserted.

Thesis (MTech (Biomedical Sciences))--Cape Peninsula University of Technology, 2015. / Previous international studies have documented a marked variation in transfusion practice for Total Hip Replacement (THR) surgery. This is despite widespread dissemination of clinical guidelines for the use of blood products. The cost and potential wastage of blood products as well as concerns regarding patient care and outcomes are important drivers of optimal blood management. The aim of this study was to audit red cell product utilisation for THR surgeries at two tertiary referral hospitals.

A hemotransfusÃo à uma necessidade que acompanha a humanidade desde seus primÃrdios. A partir do sÃculo XV vÃrios estudiosos tentaram utilizar o sangue atravÃs da transfusÃo. Somente no sÃculo XX com a descoberta dos grupos sangÃÃneos e a descriÃÃo da prova cruzada, tornaram a transfusÃo como um mÃtodo cientÃfico. Os institutos de transfusÃo de sangue foram criados na Europa a partir do ano de 1920. No Brasil somente na dÃcada de 1940 surgiram as primeiras organizaÃÃes hemoterÃpicas. Em 1949 surgiu a Sociedade Brasileira de Hematologia e Hemoterapia. A primeira Lei incentivando a doaÃÃo voluntÃria de sangue no Brasil data de 1950. Com o surgimento do movimento militar em 1964 e a constataÃÃo de que numa eventual catÃstrofe nÃo haveria sangue suficiente para atender a demanda nacional, à recomendada uma definiÃÃo na PolÃtica Nacional de Sangue. Em 1965 à editado pelo Governo Federal a Lei n 4.071 disciplinando a atividade hemoterÃpica no paÃs. E este foi o primeiro passo para regulamentar estes serviÃos. Somente em 1980 à criado o Programa Nacional de Sangue e Hemoderivados â Pro-Sangue tendo com meta a implantaÃÃo dos Hemocentros no Brasil. Comparando-se o ano de 1999 quando 2.096.190 coletas de sangue foram realizadas pela Hemorrede Nacional em relaÃÃo ao ano de 2000 quando 2.329.937 pessoas doaram sangue, notamos um aumento significativo no nÃmero de doadores em todo o Brasil. A GerÃncia Nacional de Sangue e Hemoderivados responsÃvel pelo setor de sangue no Brasil estima o percentual das doaÃÃes espontÃneas em torno de 41,74% sendo que 54,99% representam os doadores de reposiÃÃo. Em 1971 surgem os primeiros bancos de sangue privados no CearÃ. Em 1983 HEMOCE inicia suas atividades. ApÃs dez anos os Hemocentros Regionais sÃo implantados no interior do Estado. Hoje a cobertura hemoterÃpica no Cearà se aproxima dos 100% atendendo a todos os hospitais pÃblicos e privados. / The hemotransfusion is a need which has accompanied the humanity since its origins. Starting from the 15th century, several specialists tried to use the blood trough transfusion, however, only in the 20th century, with the discovery of blood groups and description of the crossed proof, transfusion was recognized as a scientific method. Blood Tranfusion Institutes were created in 1920, but in Brazil, only in the decade of 1940 apperead the first hemotherapics organizations. In this period, the Brazilian Society of Hematology and Hemotherapy was founded (in 1949) and the first law motivating the voluntary donation of blood in Brazil was written (which dates from 1950). In 1964, with the appereance of the military movement and the verification that in an eventual catastrophe there would not be enough blood to assist the national demand, was recommended a definition in the National Politics of Blood. In 1965 was edited by the Federal Government the law number 4.071 which has established rules to hemotherapic activity in the country and this was the first step to regulate this kind of service. But only in 1980 the National Program of Blood and Stems â Pro-Sangue was created tends with main goal the implantation of Hemocenters in Brazil. Comparing the year 1999, when 2.096.190 blood collections were accomplished by National Hematology Network, with the year 2000, when 2.329.937 people donated blood, we noticed a significant increase in the number of donors throughout Brazil. The National Management of Blood and Stems, responsible for the blood section in Brazil, steems the percentage of spontaneous donations around 41,74% and in this estimate 54,99% represent replacement donors. In 1971, the first private blood banks showed up in CearÃ, and in 1983, HEMOCE, started to operate. Ten years later, Regional Hemocenters was implanted in the country side of the state. Nowadays, the hemotherapic coverage in Cearà approaches 100%, assisting all of the public and private hospitals.

Blood transfusion forms a mainstay of the treatment of a variety of illnesses, and is lifesaving. Nonetheless, it is not without its risks and drawbacks. Blood transfusion is a cornerstone in the treatment of canine babesiosis. The development of blood alternatives has received attention in recent times. Blood alternatives offer much of what natural blood does but without many of the associated drawbacks. These include disease transmission, transfusion reactions, poor in vitro and in vivo shelf-life and special storage and administration requirements. One product, Oxyglobin®, is the first commercially available, veterinary-licensed, haemoglobin-based oxygen carrying solution (HBOCS). Although licenced for use in canine babesiosis, this colloidal “Oxygen Bridge” has never been evaluated against the gold standard of therapy, isovolumic packed red blood cell transfusion (pRBCT). This investigation was conducted to evaluate important aspects the equivalence of these two treatments in a field situation of naturally-infected dogs. Given the cost of HBOCS, they are unlikely to be commonly used by the practicing veterinarian in the treatment of canine babesiosis. Nonetheless, similarities in efficacy would bolster the case for and further research into blood substitutes of this and other classes, and may open the way to evaluation of HBOCS for falciparum malarial anaemia, a disease similar in many respects to canine babesiosis. / Dissertation (MMedVet)--University of Pretoria, 2007. / Companion Animal Clinical Studies / unrestricted

No description available.

No description available.

Bartonella bacilliformis is a pathogen that is endemic in some areas of the Andean region of Peru, southern Ecuador and southern Colombia. This pathogen causes so-called Carrion's disease, a biphasic disease with acute and chronic phases (called Oroya fever and "Peruvian wart" respectively1-3). In the absence or delay of antibiotic treatment, the mortality rate in the acute phase is up to 88%1. The acute phase is characterised by fever and severe anaemia and may be followed, several weeks or months later, by the chronic eruptive phase due to endothelial cell proliferation2. No animal reservoir has been identified to date and it is considered that healthy carriers act as a pathogen reservoir in endemic areas

Thesis (Ph. D.)--University of Washington, 2003. / Vita. Includes bibliographical references (leaves 110-117).

published_or_final_version / Psychology / Master / Master of Philosophy